BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 23596103)

  • 1. Effects of early chemotherapeutic treatment on learning in adolescent mice: implications for cognitive impairment and remediation in childhood cancer survivors.
    Bisen-Hersh EB; Hineline PN; Walker EA
    Clin Cancer Res; 2013 Jun; 19(11):3008-18. PubMed ID: 23596103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia.
    Winick NJ; Bowman WP; Kamen BA; Roach ES; Rollins N; Jacaruso D; Buchanan GR
    J Natl Cancer Inst; 1992 Feb; 84(4):252-6. PubMed ID: 1734087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in cognition and dendritic complexity following intrathecal methotrexate and cytarabine treatment in a juvenile murine model.
    Alexander TC; Simecka CM; Kiffer F; Groves T; Anderson J; Carr H; Wang J; Carter G; Allen AR
    Behav Brain Res; 2018 Jul; 346():21-28. PubMed ID: 29229546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.
    Land VJ; Shuster JJ; Crist WM; Ravindranath Y; Harris MB; Krance RA; Pinkel D; Pullen DJ
    J Clin Oncol; 1994 Sep; 12(9):1939-45. PubMed ID: 8083715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot study of intermediate-dose methotrexate and cytosine arabinoside, "spread-out" or "up-front," in continuation therapy for childhood non-T, non-B acute lymphoblastic leukemia. A Pediatric Oncology Group study.
    Krance RA; Newman EM; Ravindranath Y; Harris MB; Brecher M; Wimmer R; Shuster JJ; Land VJ; Pullen J; Crist W
    Cancer; 1991 Feb; 67(3):550-6. PubMed ID: 1985748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
    Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
    J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukoencephalopathy and long-term neurobehavioural, neurocognitive, and brain imaging outcomes in survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy: a longitudinal analysis.
    Cheung YT; Sabin ND; Reddick WE; Bhojwani D; Liu W; Brinkman TM; Glass JO; Hwang SN; Srivastava D; Pui CH; Robison LL; Hudson MM; Krull KR
    Lancet Haematol; 2016 Oct; 3(10):e456-e466. PubMed ID: 27658980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence of cognitive flexibility deficits and impaired emotion regulation in childhood survivors of acute lymphoblastic leukaemia: Findings from task switching study.
    Gul A; Zafar S
    J Pak Med Assoc; 2018 Mar; 68(3):848-486. PubMed ID: 29540894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No major cognitive impairment in young children with acute lymphoblastic leukemia using chemotherapy only: a prospective longitudinal study.
    Kingma A; Van Dommelen RI; Mooyaart EL; Wilmink JT; Deelman BG; Kamps WA
    J Pediatr Hematol Oncol; 2002 Feb; 24(2):106-14. PubMed ID: 11990695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurodevelopmental outcome of infants with acute lymphoblastic leukemia: a Children's Cancer Group report.
    Kaleita TA; Reaman GH; MacLean WE; Sather HN; Whitt JK
    Cancer; 1999 Apr; 85(8):1859-65. PubMed ID: 10223582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal Assessment of Neurocognitive Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia Treated on a Contemporary Chemotherapy Protocol.
    Jacola LM; Krull KR; Pui CH; Pei D; Cheng C; Reddick WE; Conklin HM
    J Clin Oncol; 2016 Apr; 34(11):1239-47. PubMed ID: 26858334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive sequelae of treatment in childhood acute lymphoblastic leukemia: cranial radiation requires an accomplice.
    Waber DP; Tarbell NJ; Fairclough D; Atmore K; Castro R; Isquith P; Lussier F; Romero I; Carpenter PJ; Schiller M
    J Clin Oncol; 1995 Oct; 13(10):2490-6. PubMed ID: 7595698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia.
    Winick N; Shuster JJ; Bowman WP; Borowitz M; Farrow A; Jacaruso D; Buchanan GR; Kamen BA
    J Clin Oncol; 1996 Oct; 14(10):2803-11. PubMed ID: 8874342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate.
    Spiegler BJ; Kennedy K; Maze R; Greenberg ML; Weitzman S; Hitzler JK; Nathan PC
    J Clin Oncol; 2006 Aug; 24(24):3858-64. PubMed ID: 16921038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group.
    Reiter A; Schrappe M; Ludwig WD; Lampert F; Harbott J; Henze G; Niemeyer CM; Gadner H; Müller-Weihrich S; Ritter J
    Blood; 1992 Nov; 80(10):2471-8. PubMed ID: 1421370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia.
    Wolfrom C; Hartmann R; Fengler R; Brühmüller S; Ingwersen A; Henze G
    J Clin Oncol; 1993 May; 11(5):827-33. PubMed ID: 8487046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of chemotherapy on cognitive function in a mouse model: a prospective study.
    Winocur G; Henkelman M; Wojtowicz JM; Zhang H; Binns MA; Tannock IF
    Clin Cancer Res; 2012 Jun; 18(11):3112-21. PubMed ID: 22467680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain Activity Associated With Attention Deficits Following Chemotherapy for Childhood Acute Lymphoblastic Leukemia.
    Fellah S; Cheung YT; Scoggins MA; Zou P; Sabin ND; Pui CH; Robison LL; Hudson MM; Ogg RJ; Krull KR
    J Natl Cancer Inst; 2019 Feb; 111(2):201-209. PubMed ID: 29790971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Memory and learning sequelae in long-term survivors of acute lymphoblastic leukemia: association with attention deficits.
    Brouwers P; Poplack D
    Am J Pediatr Hematol Oncol; 1990; 12(2):174-81. PubMed ID: 2116096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
    Weiser MA; Cabanillas ME; Konopleva M; Thomas DA; Pierce SA; Escalante CP; Kantarjian HM; O'Brien SM
    Cancer; 2004 Mar; 100(6):1179-85. PubMed ID: 15022284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.